Treated U87 and SNB19 cancer cells shared common deregulated SOX2 target genes, such as MYC, JAG1, CDK6, and SEMA3A, thus explaining the SES antitumor activity in U87 cells (fig. This evidence concerns the gene SEMA3A and cancer.